Express Scripts has opposed the price of Gilead Sciences’ Sovaldi treatment — $84,000 — since it was approved. The pharmacy benefits manager said that it was unaffordable. AbbVie’s Viekira Pak drug, recently approved by the U.S. Food and Drug Administration, has a significantly lower price, Express Scripts CMO Steve Miller.
More articles on gastroenterology:
Adopting the updated GI procedure quality metrics & what this means for practice
Making the most of 2015: New Year’s resolutions in GI
10 most-read GI/endoscopy stories of 2014
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.